Rusfertide (PTG-300) eliminates the need for therapeutic phlebotomy in both low and high-risk polycythemia vera (PV) patients

Rusfertide, a hepcidin mimetic, significantly reduced the need for therapeutic phlebotomy (TP; p < 0.0001) among patients with polycythemia vera, compared to the rate of TP before starting the drug, according to results from the phase II PTG-300-04 trial, presented during the 2021 European Hematology Association Virtual Congress. The most frequent adverse event was injection site reactions, reported among nine patients.